Lysodren (mitotane) - Perrigo Company
Isturisa (osilodrostat) - Recordati
Metopirone (metyrapone) - Perrigo Company
Antineoplastic effect of block-and-replace strategy for managing hypercortisolism caused by adrenal cortical carcinoma. (PubMed, JCEM Case Rep) - Sep 27, 2026 - "We describe 2 patients with metastatic ACC and severe Cushing syndrome treated with block-and-replace using osilodrostat or metyrapone...Unexpectedly, both experienced significant radiological tumor responses before exposure to effective cytotoxic chemotherapy and before therapeutic mitotane plasma concentrations were achieved. These cases suggest that steroidogenesis inhibition within a block-and-replace strategy may exert a direct or indirect antineoplastic effect in ACC. Although causality cannot be established, the temporal association between cortisol blockade and tumor response is compelling and warrants further prospective and translational investigation." 
Journal • Adrenal Cortex Carcinoma • Cushing's Disease • Endocrine Disorders • Genito-urinary Cancer • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42798850
 
Alfredo Berruti; Antonella Turla; Davide Lorenzo Bettini; Deborah Cosentini; Marta Laganà; Sara Rodella
 
Sep 27, 2026
 
Prev Next